Click Here to return To Results

 

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis NEJM 376:209-220,280, Montalban, X.,et al, 2017 See this aricle in Pubmed Article Abstract Among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo. Extended observation is required to determine the long-term safety and efficacy of ocrelizumab.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction B cell lymphocytes carcinoma carcinoma of breast complications efficacy herpes virus infection infection MRI,abnormal multiple sclerosis multiple sclerosis,chronic progressive multiple sclerosis,prophylaxsis multiple sclerosis,treatment of ocrelizumab placebo safety treatment of neurologic disorder viral infection,reactivation

Click Here to return To Results